Actavis Inc. Sets New 1-Year High at $170.71 (ACT)
Shares of Actavis (NYSE:ACT) hit a new 52-week high during trading on Thursday, StockRatingsNetwork reports. The stock traded as high as $170.71 and last traded at $167.64, with a volume of 1,035,681 shares trading hands. The stock had previously closed at $168.00.
A number of analysts have recently weighed in on ACT shares. Analysts at Zacks downgraded shares of Actavis from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, November 28th. They now have a $172.00 price target on the stock. Separately, analysts at UBS AG raised their price target on shares of Actavis from $155.00 to $186.00 in a research note to investors on Wednesday, October 30th. They now have a “buy” rating on the stock. Finally, analysts at Susquehanna raised their price target on shares of Actavis from $165.00 to $170.00 in a research note to investors on Wednesday, October 30th. They now have a “neutral” rating on the stock. Seven analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $153.94.
Actavis has a one year low of $82.02 and a one year high of $170.51. The stock has a 50-day moving average of $163.3 and a 200-day moving average of $143.2. The company’s market cap is $29.241 billion.
Actavis (NYSE:ACT) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.09 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $2.09. The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $2.04 billion. The company’s quarterly revenue was up 56.7% on a year-over-year basis.
Actavis, Inc formerly Watson Pharmaceuticals, Inc, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (NYSE:ACT) pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.